Genetically modified mouse models have been very useful in research on neurodegenerative disorders,and the proposed program will take maximal advantage of this valuable resource. The main goal of Core C isto help the project leaders address their research questions conclusively with the minimal number of animalsand experiments possible. To achieve this goal, we propose six specific aims.
Aim 1 : Maintain all animals ina manner that ensures the reliable selection of experimental and control groups for timely distribution to thedifferent projects. Rodents will be housed in specific-pathogen-free animal care facilities in the Gladstonebuilding at UCSF's Mission Bay campus and in the Medical Teaching Facility at UCSD's La Jolla campus.Detailed information on these animals will be recorded in a database that is accessible to all project leadersand their coworkers via the computer networks of the Gladstone Institutes and the University of California.
Aim 2 : Breed the different lines of genetically modified mice and determine the genotype of the offspring bypolymerase chain reaction (PCR). The core personnel have ample experience in genotyping geneticallymodified mice and maintaining complex animal databases.
Aim 3 : Receive mice from the Gladstonemicroinjection facility and blastocyst core and identify new genetically modified lines of mice. Gladstone andUCSD maintain state-of-the-art facilities for transgene microinjection and gene targeting.
Aim 4 : Periodicallyanalyze all lines of mice to confirm that levels and patterns of (trans)gene expression have remained stable.Cerebral levels of transgene expression will be tested by quantitative fluorogenic PCR. The distribution oftransgene expression will be characterized in collaboration with Core D. We will also collaborate closely withCore D and veterinary staff to continually optimize our protocols for the anesthesia and perfusion of animalsand for the removal, dissection, and proper storage of neural tissues.
Aim 5 : Ship mice to Dr. Masliah atUCSD and to investigators at other institutions, and provide the investigators with advice on the genotypingand husbandry of the mice. We have distributed our animal models to many institutions around the world andwill continue to make our models available to the scientific community.
Aim 6 : Maintain a comprehensivemouse colony database to efficiently store and manage detailed information for current and futureexperiments. We will continue to optimize our database to store mouse colony data in a clear and accessiblemanner, minimize the effort and time required to enter data, and facilitate the development of individualizedmodules to best suit the needs of specific investigators and studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG022074-06
Application #
7468579
Study Section
Special Emphasis Panel (ZAG1-ZIJ-3 (J3))
Project Start
2008-06-01
Project End
2013-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
6
Fiscal Year
2008
Total Cost
$391,552
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Valera, Elvira; Spencer, Brian; Mott, Jennifer et al. (2017) MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Front Mol Neurosci 10:329
Valera, Elvira; Spencer, Brian; Fields, Jerel A et al. (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5:2
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) ?-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-?, ?-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34

Showing the most recent 10 out of 254 publications